Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marjo Apajasalo"'
Publikováno v:
Psychiatria Fennica, Vol 50, Pp 132-143 (2019)
Health-related quality of life (HRQoL) has improved in adults in Finland. Much less is known about HRQoL of adolescents. The aim of the present study was to compare HRQoL between school samples from 1996 and 2013. Furthermore, we investigated age a
Externí odkaz:
https://doaj.org/article/4f2a2dcaecba43249374bef4a39a9c6b
Autor:
Matthias Heringlake, Marjo Apajasalo, Matti Kivikko, Piero Pollesello, S Mardiguian, Caitlin Smare, Evelina Bertranou
Publikováno v:
Journal of medical economics. 19(5)
To evaluate the cost-benefit of using levosimendan compared with dobutamine, in the perioperative treatment of patients undergoing cardiac surgery who require inotropic support.A two-part Markov model was designed to simulate health-state transitions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb22ffd561da794d2736e274964d7cfe
https://pubmed.ncbi.nlm.nih.gov/26707159
https://pubmed.ncbi.nlm.nih.gov/26707159
Autor:
Ilkka, Sipilä, Harri, Sintonen, Heikki, Hietanen, Marjo, Apajasalo, Soili, Alanne, Anna-Mari, Viita, Eeva, Leinonen
Publikováno v:
Acta paediatrica (Oslo, Norway : 1992). 99(11)
To assess the effects of recombinant human growth hormone (rhGH) treatment in children with Prader-Willi syndrome.A 1-year study and an observational follow-up visit 10 years later.In 20 patients with Prader-Willi syndrome (PWS): clinical assessment,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0c0091a9526de618fd488d92ba017976
https://pubmed.ncbi.nlm.nih.gov/20545932
https://pubmed.ncbi.nlm.nih.gov/20545932
Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson's disease
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 2(2)
The objective was to assess uncertainty in a cost-utility analysis of adjunct entacapone treatment with levodopa among Parkinson's disease patients by probabilistic sensitivity analysis using second-order simulation methods. The cost-effectiveness of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f81d521f53be99eca7402068dd003c2
https://pubmed.ncbi.nlm.nih.gov/19807321
https://pubmed.ncbi.nlm.nih.gov/19807321
Publikováno v:
Current medical research and opinion. 21(7)
A Markov model was developed to evaluate the cost-effectiveness of levodopa/carbidopa/entacapone (LCE;Stalevo), in the treatment of patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (wearing-off). LCE, with or without other an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7d14e5582eb00afcd2906b9d9653203
https://pubmed.ncbi.nlm.nih.gov/16004667
https://pubmed.ncbi.nlm.nih.gov/16004667
Publikováno v:
Critical Care. 8:P88
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a79b3cc16fc76345f04281969963d36
https://doi.org/10.1186/cc2555
https://doi.org/10.1186/cc2555
Autor:
Marjo Apajasalo, Kirsi-Maija Kaukonen, Heidi Turunen, Toni Sarapohja, Stephan M. Jakob, Jukka Takala, Esko Ruokonen
Publikováno v:
Turunen, Heidi; Jakob, Stephan; Ruokonen, Esko; Kaukonen, Kirsi-Maija; Sarapohja, Toni; Apajasalo, Marjo; Takala, Jukka (2015). Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care: an economic evaluation. Critical care, 19(67), p. 67. BioMed Central 10.1186/s13054-015-0787-y
Critical Care
Critical Care
Introduction Dexmedetomidine was shown in two European randomized double-blind double-dummy trials (PRODEX and MIDEX) to be non-inferior to propofol and midazolam in maintaining target sedation levels in mechanically ventilated intensive care unit (I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f95c4e625b0d849076f8748a048da7b0